Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06383026). This is a study registration, not published results. Lead sponsor: Medical College of Wisconsin. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 130 participants (ESTIMATED). Conditions: Breast Cancer. Interventions: DIAGNOSTIC_TEST: Breast Cancer Screening; OTHER: Survey/Interview; OTHER: Focus Group. Primary outcome measures: Callback and Biopsy Rates after Breast Cancer Screening , 3.5 years; Reflexive Thematic Analysis of the Physical, Cognitive, and Emotional Experience of Breast Cancer Screening in Individuals on Hormone Therapy , 3.5 years; Reflexive Thematic Analysis on the Individual & System-Level Barriers to Breast Cancer Screening , 3.5 years. Brief summary: This investigation is a prospective breast cancer screening study open to all individuals on hormone therapy. Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with hormone therapy and family cancer history and 2) investigate individuals on hormone therapy perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening.